How should resistant hypertension be managed in a patient with acute heart‑failure decompensation?

Management of Resistant Hypertension in Acute Heart Failure Decompensation

In patients with resistant hypertension and acute HF decompensation, prioritize aggressive decongestion with intravenous loop diuretics and vasodilators (particularly IV nitroglycerin) while continuing guideline-directed medical therapy (GDMT) unless contraindicated, then add spironolactone once stabilized if not already prescribed.

Immediate Acute Management (First 24-48 Hours)

Primary Interventions

Intravenous loop diuretics are first-line therapy for congestion in acute HF decompensation 1. The hypertensive presentation actually represents vascular redistribution rather than pure volume overload 2, 3, making vasodilators equally critical.

• Start IV loop diuretics (furosemide, bumetanide, or torsemide) immediately for congestion 1
• Add IV vasodilators for dyspnea at rest—these are CLASS I recommendations 1
  • IV nitroglycerin at high doses can rapidly reduce cardiac filling pressures and achieve pulmonary decongestion 2
  • Consider IV nitroprusside if significant low cardiac output with congestion 4

Critical Monitoring

Monitor frequently until stabilized 1:

• Heart rate, blood pressure, oxygen saturation
• Fluid balance and urine output (may require bladder catheterization)
• Serum electrolytes and renal function (check regularly in first 24h if shock or significant renal dysfunction present)

What NOT to Do

Do not routinely discontinue GDMT (ACE inhibitors/ARBs, beta-blockers, MRAs) for mild renal function decrease or asymptomatic blood pressure reduction during hospitalization 5. This is a CLASS I recommendation that contradicts older, more conservative approaches.

Avoid calcium channel blockers (diltiazem, verapamil) in acute HF with systolic dysfunction—CLASS III recommendation 1. These have negative inotropic effects and can worsen outcomes 6.

Addressing Diuretic Resistance

If inadequate response within 48 hours of IV loop diuretics 7:

1. Double the loop diuretic dose first
2. Switch to IV administration if using oral (same dose initially)
3. Add sequential nephron blockade: thiazide diuretic (metolazone) or low-dose spironolactone 1
   • This combination is more effective with fewer side effects than higher loop diuretic doses alone
4. Consider continuous furosemide infusion rather than bolus dosing 1

Common pitfall: Using high IV loop diuretic doses (>0.1 mg/kg) can cause reflex vasoconstriction 1. The combination approach is superior.

Stabilization Phase: Optimizing GDMT

Continue Existing Therapies

Beta-blockers should be continued or dose-reduced but NOT discontinued unless cardiogenic shock is present 8, 5. This is CLASS I evidence. Down-titration may be required in severe decompensation, particularly if requiring inotropic support 8.

ACE inhibitors/ARBs should be continued when patient is stabilized, not in the first few hours 1. They should be introduced/reintroduced once hemodynamically stable 1.

Addressing the Resistant Hypertension Component

Once acute decompensation is controlled, the resistant hypertension requires specific management per the 2024 ESC guidelines 9:

Step 1: Reinforce lifestyle measures (especially sodium restriction <2400 mg/day) and optimize the 3-drug foundation:

• RAS blocker (ACE inhibitor or ARB)
• Long-acting calcium channel blocker (dihydropyridine type—amlodipine or felodipine are safe in HF 6)
• Thiazide-like diuretic (chlorthalidone or indapamide preferred 10)

Step 2: Add low-dose spironolactone 9, 10

• This is the CLASS IIa recommendation for resistant hypertension
• Should be considered as soon as renal function and potassium permit 11, 5
• Critical monitoring: Check electrolytes and creatinine every 1-3 months when using triple therapy (ACEi/ARB + MRA + diuretic) 7
• Most clinicians stop the MRA before stopping the ACEi/ARB if hyperkalemia develops 7

Step 3: If spironolactone ineffective or not tolerated 9, 10:

• Eplerenone (alternative MRA)
• Beta-blocker if not already prescribed (carvedilol preferred in HFrEF with refractory hypertension due to combined α₁-β₁-β₂ blockade 6)
• Bisoprolol or doxazosin as alternatives

Step 4: Consider additional agents 10:

• Hydralazine (especially if HFrEF—combine with isosorbide)
• Centrally acting agents (clonidine patch) if beta-blockers contraindicated
• Avoid: Moxonidine and other centrally acting norepinephrine-depleting agents showed increased mortality in HF 6

Special Considerations for HF Phenotypes

HFrEF (EF ≤40%)

The foundation includes ACEi/ARB (or ARNI), beta-blocker, MRA, and SGLT2 inhibitor 9. All have BP-lowering effects and improve outcomes.

HFpEF

SGLT2 inhibitors are recommended for symptomatic HFpEF with modest BP-lowering properties 9. ARBs and/or MRAs may be considered if BP remains above target to reduce HF hospitalizations 9.

Managing Complications

Worsening Renal Function

A creatinine increase >30% or >26 μmol/L from baseline requires assessment 7:

• Most common cause is hypovolemia—assess volume status, consider reducing/temporarily stopping diuretics
• Avoid NSAIDs and other nephrotoxic agents
• Reassess within 7 days if creatinine changes >20-30%
• Consider nephrology consultation if interventions fail

Hypotension Management

Rather than stopping GDMT 7:

• Stagger vasoactive medications (no 2 drugs within 2 hours of each other)
• Split medications into smaller, more frequent doses
• Give beta-blockers with meals to slow absorption
• Discontinue non-prognostic BP medications (calcium blockers, alpha-blockers) first
• Titrate more slowly when hypovolemia present

Hyponatremia (Na <135 mEq/L)

• Ensure adequate potassium and chloride supplementation 7
• Discontinue combination diuretic therapy as early as possible
• Consider acetazolamide for metabolic alkalosis if diuretics cannot be reduced 7
• Tolvaptan highly effective when sodium <130 mEq/L 7, 11
• Fluid restriction typically <2000 mL/24h (aggressive restrictions of 1000-1500 mL are now questioned) 7

Key Algorithmic Approach

1. Immediate: IV loop diuretics + IV vasodilators (nitroglycerin) + oxygen + continue beta-blockers (unless shock)
2. First 24-48h: Aggressive decongestion monitoring response; add thiazide if diuretic resistance
3. Stabilization: Reintroduce/optimize ACEi/ARB, continue beta-blocker, initiate/continue MRA
4. Post-stabilization: Address resistant hypertension with spironolactone addition if not already prescribed
5. Refractory cases: Sequential addition per resistant hypertension algorithm, avoiding contraindicated agents in HF

The critical paradigm shift: Hypertensive acute HF is primarily a vascular redistribution problem, not pure volume overload 2, 3. This justifies the aggressive use of vasodilators alongside—not after—diuretics, which differs from traditional volume-focused approaches.